Antimicrobial resistance (AMR) is accelerating at an alarming pace, undermining decades of medical progress and rendering many antibiotics ineffective. As the global healthcare community confronts the prospect of a post-antibiotic era, innovative tools are urgently needed to expand our therapeutic arsenal. Among the most promising candidates are bacteriophages—viruses that naturally infect and kill bacteria.
At Chelonia, we are particularly interested in how phages, and in particular engineered “designer phages,” can be integrated into advanced strategies to counteract AMR. These highly specific biological agents offer a unique combination of selectivity, adaptability, and biocompatibility. Unlike conventional antibiotics, phages can be tuned to target specific bacterial strains without disturbing the beneficial microbiota—a critical advantage in clinical settings where microbial balance matters.
Today, synthetic biology and high-throughput molecular tools allow us to genetically program phages with new properties. Designer phages can be constructed to bypass bacterial resistance mechanisms, deliver targeted therapeutic payloads, or even emit diagnostic signals when they encounter specific pathogens. These applications are no longer speculative: early clinical trials, compassionate-use cases, and growing investment from public and private sectors are driving real-world deployment.
Chelonia is exploring how artificial intelligence and machine learning can unlock the next generation of phage-based therapies. AI can accelerate phage-host matching by analyzing genomic and phenotypic data from bacterial isolates, predicting which phages are most likely to be effective against resistant strains. In silico screening tools can help prioritize candidates, simulate interactions, and optimize phage cocktails without laborious lab work. We are particularly interested in how these tools can support personalized therapies, where the patient’s infection profile guides the selection of a tailored phage treatment in near real time.
Moreover, machine learning can assist in engineering the phages themselves. By analyzing functional genomics and protein interaction networks, AI can guide the insertion or removal of specific genes to enhance therapeutic action, suppress unwanted traits, or add functionalities like fluorescence or payload delivery. This level of control over phage biology opens the door to truly programmable antimicrobials—dynamic tools that can evolve alongside the pathogens they are designed to combat.
Beyond therapy, phages also have transformative potential in diagnostics, infection control, and even food safety. For instance, phages can be used to detect bacterial contamination through engineered fluorescence, or to prevent the spread of pathogens in agricultural supply chains. In the context of microbiome engineering, designer phages may help restore microbial balance in patients with inflammatory or metabolic conditions, creating synergies between infectious disease management and broader health interventions.
At Chelonia, we view phage-based innovation as a critical pillar of the future antimicrobial ecosystem. But harnessing this potential requires more than good science—it demands a strategic integration of AI, clinical data, regulatory insight, and system-level thinking. That’s why we are working to build a multidisciplinary approach, where digital tools, molecular biology, and translational research come together to accelerate impact.
We are currently evaluating strategic partnerships to co-develop phage-based AI pipelines, benchmark computational methods for phage selection, and engage in translational research efforts aimed at clinical validation. If you are working at the intersection of phage therapy, bioinformatics, or AMR, we would be pleased to connect.
Chelonia is committed to driving forward a science-based, AI-augmented roadmap for combating antimicrobial resistance—where precision phages may soon stand alongside or even replace conventional antibiotics.
